References
- Niemeyer C. M., Arico M., Basso G., Biondi A., Cantu A. Rajnoldi, Creutzig U., Haas O., Harbott J., Hasle H., Kerndrup G., Locatelli F., Mann G., Stollmann-Gibbels B., van't Veer-Korthof E. T., van Wering E., Zimmermann M. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89: 3534–3543
- Emanuel P. D., Shannon K. M., Castleberry R. P. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Molecular Medicine Today 1996; 2: 468–475
- Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593–602
- Miyamoto M., Fujita T., Kimura Y., Maruyama M., Harada H., Sudo Y., Miyata T., Taniguchi T. Regulated expressior of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988; 54: 903–913
- Harada H., Fujita T., Miyamoto M., Kimura Y., Maruyama M., Furia A., Miyata T., Taniguchi T. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989; 58: 729–739
- Willman C. L., Sever C. E., Pallavicini M. G., Harada H., Tanaka N., Slovak M. L., Yamamoto H., Harada K., Meeker T. C., List A. F., et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968–971
- Tanaka N., Ishihara M., Kitagawa M., Harada H., Kimura T., Matsuyama T., Lamphier M. S., Aizawa S., Mak T. W., Taniguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829–839
- Harada H., Kitagawa M., Tanaka N., Yamamoto H., Harada K., Ishihara M., Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993; 259: 971–974
- Harada H., Kondo T., Ogawa S., Tamura T., Kitagawa M., Tanaka N., Lamphier M. S., Hirai H., Taniguchi T. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994; 9: 3313–3320
- Side L. E., Emanuel P. D., Taylor B., Franklin J., Thompson P., Castleberry R. P., Shannon K. M. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92: 267–272
- Flotho C., Valcamonica S., Mach-Pascula S., Schmahl G., Corral L., Ritterbach J., Hasle H., Arico' M., Biondi A., Niemeyer C. M. Ras mutation and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999; 13: 32–37
- Kalra R., Paderanga D. C., Olson K., Shannon K. M. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 1994; 84: 3435–3439
- Ramos-Morales F., Dominguez A., Rios R. M., Barroso S. I., Infante C., Schweighoffer F., Tocque B., Pintor-Toro J. A., Tortolero M. Adenosine deaminase is a specific partner for the Grb2 isoform Grb3–3. Biochemical & Biophysical Research Communication 1997; 237: 735–740